Myriad Genetics - MYGN Stock Price Target and Predictions

  • Consensus Rating: Hold
  • Consensus Price Target: $28.33
  • Forecasted Upside: 11.68 %
  • Number of Analysts: 2
  • Breakdown:
  • 1 Sell Ratings
  • 1 Hold Ratings
  • 0 Buy Ratings
  • 0 Strong Buy Ratings
$25.37
▼ -0.16 (-0.63%)

This chart shows the closing price for MYGN by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Myriad Genetics Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for MYGN and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for MYGN

Analyst Price Target is $28.33
▲ +11.68% Upside Potential
This price target is based on 2 analysts offering 12 month price targets for Myriad Genetics in the last 3 months. The average price target is $28.33, with a high forecast of $32.00 and a low forecast of $23.00. The average price target represents a 11.68% upside from the last price of $25.37.

This chart shows the closing price for MYGN for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Hold

The current consensus among 2 investment analysts is to hold stock in Myriad Genetics. This rating has held steady since February 2021, when it changed from a Sell consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 0 buy ratings
  • 3 hold ratings
  • 3 sell ratings
2/24/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 3 hold ratings
  • 0 sell ratings
5/25/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 3 hold ratings
  • 1 sell ratings
8/23/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 2 hold ratings
  • 1 sell ratings
11/21/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 2 hold ratings
  • 1 sell ratings
2/19/2022
  • 0 strong buy ratings
  • 0 buy ratings
  • 2 hold ratings
  • 1 sell ratings
5/20/2022
  • 0 strong buy ratings
  • 0 buy ratings
  • 1 hold ratings
  • 1 sell ratings
7/19/2022
  • 0 strong buy ratings
  • 0 buy ratings
  • 1 hold ratings
  • 1 sell ratings
8/18/2022

Latest Recommendations

  • 0 strong buy ratings
  • 0 buy ratings
  • 1 hold ratings
  • 1 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
8/9/2022CowenBoost Target$32.00Low
8/5/2022SVB LeerinkBoost TargetMarket Perform$26.00 ➝ $30.00Low
7/19/2022CowenSet Target$25.00Low
4/19/2022The Goldman Sachs GroupLower TargetSell$26.00 ➝ $23.00High
11/3/2021SVB LeerinkLower TargetMarket Perform$36.00 ➝ $35.00High
6/15/2021Raymond JamesInitiated CoverageMarket PerformLow
6/3/2021The Goldman Sachs GroupInitiated CoverageSell$25.00High
2/24/2021SVB LeerinkBoost TargetMarket Perform$20.00 ➝ $33.00Low
11/10/2020Piper SandlerBoost TargetNeutral$14.00 ➝ $18.00High
8/14/2020Needham & Company LLCReiterated RatingHoldHigh
5/6/2020Needham & Company LLCReiterated RatingHoldLow
5/6/2020JPMorgan Chase & Co.Lower TargetUnderweight$14.00 ➝ $12.00Low
5/6/2020Piper SandlerLower TargetPositive ➝ Neutral$20.00 ➝ $14.00High
4/2/2020Bank of AmericaLower TargetUnderperform$16.00 ➝ $13.00Medium
3/26/2020BarclaysLower TargetUnderweight$14.00 ➝ $10.00Low
3/6/2020JPMorgan Chase & Co.Lower TargetUnderweight$17.00 ➝ $14.00Medium
2/7/2020Piper SandlerLower Target$22.00 ➝ $20.00Low
2/7/2020JPMorgan Chase & Co.Lower TargetUnderweight$20.00 ➝ $17.00High
1/3/2020Needham & Company LLCInitiated CoverageStrong-Buy$36.00Low
11/5/2019Piper Jaffray CompaniesLower Target$40.00 ➝ $22.00High
11/5/2019Needham & Company LLCReiterated RatingHoldHigh
11/5/2019SVB LeerinkLower TargetMarket Perform$37.00 ➝ $28.00High
11/5/2019BarclaysLower TargetUnderweight$22.00 ➝ $18.00High
9/26/2019Bank of AmericaDowngradeNeutral ➝ Underperform$30.00 ➝ $28.00High
9/24/2019Piper Jaffray CompaniesReiterated RatingHoldLow
8/26/2019Needham & Company LLCReiterated RatingHoldLow
8/23/2019BarclaysSet TargetSell$22.00Medium
8/14/2019BarclaysDowngradeEqual Weight ➝ UnderweightHigh
8/14/2019Deutsche Bank AktiengesellschaftLower TargetHold$45.00 ➝ $35.00High
8/14/2019Piper Jaffray CompaniesDowngradeOverweight ➝ Neutral$45.00 ➝ $40.00High
8/5/2019Deutsche Bank AktiengesellschaftBoost TargetHold$32.00 ➝ $45.00Medium
8/2/2019Bank of AmericaUpgradeUnderperform ➝ NeutralHigh
8/1/2019BarclaysUpgradeUnderweight ➝ Equal Weight$18.00 ➝ $40.00High
7/29/2019Needham & Company LLCDowngradeStrong-Buy ➝ HoldLow
7/9/2019CowenDowngradeOutperform ➝ Market Perform$26.64High
6/14/2019BarclaysBoost TargetUnderweight$18.00 ➝ $20.00High
5/14/2019Needham & Company LLCReiterated RatingStrong-Buy$32.00Low
3/12/2019Needham & Company LLCReiterated RatingPositive ➝ Strong-Buy$37.00 ➝ $41.00High
1/4/2019CowenUpgradeMarket Perform ➝ OutperformHigh
1/3/2019BarclaysLower TargetUnderweight ➝ Underweight$23.00 ➝ $21.00Medium
1/2/2019Needham & Company LLCInitiated CoverageStrong-Buy ➝ Strong-Buy$36.00Medium
12/9/2018The Goldman Sachs GroupUpgradeSell ➝ Neutral$32.72Low
11/30/2018The Goldman Sachs GroupUpgradeSell ➝ Neutral$28.00 ➝ $32.00Medium
11/5/2018Deutsche Bank AktiengesellschaftBoost TargetHold ➝ Hold$37.00 ➝ $43.00High
10/10/2018Morgan StanleyBoost TargetOverweight ➝ Overweight$51.00 ➝ $54.00High
10/10/2018Piper Jaffray CompaniesUpgradeNeutral ➝ Overweight$38.00 ➝ $53.00High
9/11/2018BarclaysLower TargetUnderweight ➝ Underweight$30.00 ➝ $25.00Medium
9/5/2018BarclaysDowngradeEqual Weight ➝ Underweight$38.00 ➝ $30.00High
8/22/2018Bank of AmericaBoost TargetUnderperform ➝ Sell$31.00 ➝ $34.00High
8/22/2018BarclaysBoost TargetEqual Weight ➝ Equal Weight$35.00 ➝ $38.00High
8/22/2018StephensBoost TargetOverweight$45.00 ➝ $52.00High
8/22/2018Morgan StanleyBoost TargetOverweight ➝ Overweight$47.00 ➝ $49.00High
8/22/2018Piper Jaffray CompaniesBoost TargetNeutral$38.00High
7/16/2018Bank of AmericaBoost TargetUnderperform ➝ Underperform$20.00 ➝ $31.00Low
7/11/2018Morgan StanleyUpgradeEqual Weight ➝ Overweight$35.00 ➝ $55.00High
5/9/2018Morgan StanleyBoost TargetEqual Weight ➝ Equal Weight$33.00 ➝ $35.00Medium
5/8/2018BTIG ResearchSet TargetBuy$42.00Medium
3/21/2018Morgan StanleyUpgradeUnderweight ➝ Equal Weight$28.00Medium
2/7/2018BTIG ResearchSet TargetBuy$44.00High
2/7/2018SVB LeerinkBoost TargetMarket Perform ➝ Market Perform$33.00 ➝ $35.00High
2/7/2018Morgan StanleyBoost TargetUnderweight ➝ Underweight$26.00 ➝ $28.00High
1/29/2018The Goldman Sachs GroupInitiated CoverageSell ➝ Sell$32.00High
1/22/2018BarclaysBoost TargetEqual Weight ➝ Equal Weight$30.00 ➝ $35.00Low
1/16/2018BTIG ResearchSet TargetBuy$41.00High
1/8/2018BarclaysReiterated RatingHold$30.00High
1/5/2018BTIG ResearchInitiated CoverageBuy ➝ Buy$41.00Medium
1/3/2018StephensSet TargetBuy$45.00Medium
11/8/2017Deutsche Bank AktiengesellschaftBoost TargetHold$28.00 ➝ $30.00N/A
11/8/2017Morgan StanleyBoost TargetUnderweight$24.00 ➝ $26.00N/A
10/6/2017Morgan StanleyReiterated RatingUnderweight$17.00 ➝ $24.00N/A
10/2/2017SVB LeerinkReiterated RatingMkt Perform ➝ Market Perform$31.00Medium
9/22/2017StephensReiterated RatingOverweight$36.00 ➝ $40.00Low
9/17/2017CowenReiterated RatingHold$25.00Low
8/18/2017Deutsche Bank AktiengesellschaftUpgradeSell ➝ Hold$27.86 ➝ $15.00High
(Data available from 8/18/2017 forward)

News Sentiment Rating

0.72 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 1 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
1/20/2022
  • 1 very positive mentions
  • 0 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
2/19/2022
  • 6 very positive mentions
  • 4 positive mentions
  • 4 negative mentions
  • 0 very negative mentions
3/21/2022
  • 0 very positive mentions
  • 0 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
4/20/2022
  • 2 very positive mentions
  • 6 positive mentions
  • 1 negative mentions
  • 2 very negative mentions
5/20/2022
  • 1 very positive mentions
  • 3 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
6/19/2022
  • 2 very positive mentions
  • 3 positive mentions
  • 2 negative mentions
  • 1 very negative mentions
7/19/2022
  • 7 very positive mentions
  • 9 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
8/18/2022

Current Sentiment

  • 7 very positive mentions
  • 9 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Myriad Genetics logo
Myriad Genetics, Inc., a genetic testing and precision medicine company, develops and commercializes genetic tests in the United States and internationally. The company offers molecular diagnostic tests for use in oncology, and women's and mental health applications. It provides MyRisk Hereditary Cancer Test, a DNA sequencing test for assessing the risks for hereditary cancers; BRACAnalysis CDx Germline Companion Diagnostic Test, a DNA sequencing test to help determine the therapy for patients with metastatic breast, ovarian, metastatic pancreatic, or metastatic prostate cancer with deleterious or suspected deleterious germline BRCA variants; and MyChoice CDx Companion Diagnostic Test, a tumor test that determines homologous recombination deficiency status in patients with ovarian cancer. The company also offers Prolaris Prostate Cancer Prognostic Test, a RNA expression tumor analysis for assessing the aggressiveness of prostate cancer; EndoPredict Breast Cancer Prognostic Test, a RNA expression test for assessing the aggressiveness of breast cancer; Precise Tumor, a solution for precision oncology; and Prequel Prenatal Screen, a non-invasive prenatal screening test conducted using maternal blood to screen for severe chromosomal disorders in a fetus. In addition, it provides Foresight Carrier Screen, a prenatal test for future parents to assess their risk of passing on a recessive genetic condition to their offspring; and GeneSight Psychotropic Mental Health Medication Test, a DNA genotyping test to aid psychotropic drug selection for patients suffering from depression, anxiety, ADHD, and other mental health conditions. Myriad Genetics, Inc. has a strategic collaboration with Illumina, Inc. and Intermountain Precision Genomics for an offering of germline and somatic tumor testing services. The company was founded in 1991 and is headquartered in Salt Lake City, Utah.
Read More

Today's Range

Now: $25.37
Low: $25.11
High: $25.46

50 Day Range

MA: $21.86
Low: $16.45
High: $27.88

52 Week Range

Now: $25.37
Low: $16.02
High: $36.95

Volume

13,183 shs

Average Volume

588,609 shs

Market Capitalization

$2.05 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.7

Frequently Asked Questions

What sell-side analysts currently cover shares of Myriad Genetics?

The following sell-side analysts have issued reports on Myriad Genetics in the last year: Cowen Inc., StockNews.com, SVB Leerink LLC, The Goldman Sachs Group, Inc., and TheStreet.
View the latest analyst ratings for MYGN.

What is the current price target for Myriad Genetics?

3 Wall Street analysts have set twelve-month price targets for Myriad Genetics in the last year. Their average twelve-month price target is $28.33, suggesting a possible upside of 11.7%. Cowen Inc. has the highest price target set, predicting MYGN will reach $32.00 in the next twelve months. The Goldman Sachs Group, Inc. has the lowest price target set, forecasting a price of $23.00 for Myriad Genetics in the next year.
View the latest price targets for MYGN.

What is the current consensus analyst rating for Myriad Genetics?

Myriad Genetics currently has 1 sell rating and 1 hold rating from Wall Street analysts. The stock has a consensus analyst rating of "Hold." A "hold" rating indicates that analysts believe investors should keep any existing positions they have in MYGN, but not buy more shares or sell existing shares.
View the latest ratings for MYGN.

What other companies compete with Myriad Genetics?

How do I contact Myriad Genetics' investor relations team?

Myriad Genetics' physical mailing address is 320 WAKARA WAY, SALT LAKE CITY UT, 84108. The company's listed phone number is (801) 584-3600 and its investor relations email address is [email protected] The official website for Myriad Genetics is www.myriad.com. Learn More about contacing Myriad Genetics investor relations.